Report Summary
In 2011, the Branded PharmaVitae Universe achieved sales of $558bn having experienced a compound annual growth rate (CAGR) of 9.3% between 2003 and 2010, and a net sales growth of $253bn. However, during 2011–16 sales are forecast to grow by a CAGR of only 1.0%, with no growth forecast in 2012, and branded prescription sales rising by just $29bn by 2016.
Your key questions answered
- Evaluate the evolving prescription pharmaceutical landscape and how this is set to impact Pharma out to 2016
- Quantify the size and growth of the pharmaceutical market
- Assess drivers and resistors of the prescription pharmaceutical market
Branded Prescription Pharmaceutical Market
Published: February 2012
No.OF Pages: 45
Price: Single User License US$ 5700 Corporate User License US$ 14250
Table of Contents
EXECUTIVE SUMMARY
Strategic scoping and focus
Key findings
Related reports
FORECAST PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
The Branded PharmaVitae Universe will experience sales growth of only 1.0% per year out to 2016
Newly launched and core drugs will collectively offset the sales loss from expiry products
The pharmaceutical industry continues to expand in the biologic sector
Injectable drugs are set to drive market growth
The industry will derive the majority of its sales from externally sourced products by 2016
The rest of world markets alone will offset the sales decline in the US
Secondary care therapy areas are becoming a priority for pharma
Sales of blockbuster drugs are expected to contract during 2011–16
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
The Branded PharmaVitae Universe
List of Tables
Table: Forecast prescription pharma sales ($bn) and year-on-year growth rate (%) for the Branded PharmaVitae Universe, 2011–16
Table: Combined global sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2011–16
Table: Combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2011–16
Table: Combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2011–16
Table: Combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2011–16
Table: Combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2011–16
Table: Combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2011–16
Table: Global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2011–16
Table: Forecast sales for the Branded PharmaVitae Universe ($m), 2011–16
List of Figures
Figure: Drivers and resistors for global sales growth of prescription products from the Branded PharmaVitae Universe, 2011–16
Figure: Global prescription pharma sales ($bn) and year-on-year growth rate (%), 2003–16
Figure: Combined global sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2003–16
Figure: Difference in global combined sales for the Branded PharmaVitae Universe for launch, core, expiring, and generic prescription products ($bn), 2011–16
Figure: Sales growth for the Branded PharmaVitae Universe, by launch/core/expiry/generic portfolio, 2011–16
Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2003–16
Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by molecule type ($bn), 2011–16
Figure: Sales growth for the Branded PharmaVitae Universe, by molecule type, 2011–16
Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2003–16
Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product delivery mechanism ($bn), 2011–16
Figure: Sales growth for the Branded PharmaVitae Universe, by delivery mechanism, 2011–16
Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2003–16
Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product source ($bn), 2011–16
Figure: Sales growth for the Branded PharmaVitae Universe, by product source, 2011–16
Figure: Combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2003–16
Figure: Difference in combined prescription sales for the Branded PharmaVitae Universe, by geography ($bn), 2011–16
Figure: Sales growth for the Branded PharmaVitae Universe, by geography, 2011–16
Figure: Combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2003–16
Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by therapy area ($bn), 2011–16
Figure: Sales growth for the Branded PharmaVitae Universe, by therapy area, 2011–16
Figure: Global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2003–16
Figure: Difference in combined global prescription sales for the Branded PharmaVitae Universe, by product value ($bn), 2011 and 2016
Figure: Sales growth for the Branded PharmaVitae Universe, by product value, 2011–16